Quantcast

Latest Celgene Stories

2014-07-28 16:26:36

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018https://www.reportbuyer.com/product/2225690/Global-Non-Hodgkin-Lymphoma-Therapeutics-Market-2014-2018.htmlAbout Non-Hodgkin Lymphoma (NHL) and its Diagnostic ProceduresNon-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die....

2014-06-25 08:32:07

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...

2014-06-05 12:29:26

CHICAGO, June 5, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Pharmacyclics (Nasdaq:PCYC-Free Report), AbbVie (NYSE:ABBV-Free Report), Gilead (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report) and Celgene (Nasdaq:CELG-Free Report)....

2014-05-06 08:33:10

Biotech Leadership with Significant Strategic and Financial Expertise SAN DIEGO, May 6, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, announced today the appointment of two new members to its Board of Directors. The new directors, Robert Baltera and Stuart Collinson, Ph.D., bring considerable biotech experience to the Arcturus Board. http://photos.prnewswire.com/prnvar/20130531/MM24393LOGO Robert "Bob" Baltera is a...

2014-05-01 08:37:43

CHICAGO, May 1, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Celgene (Nasdaq:CELG-Free Report), Gilead (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Biogen (Nasdaq:BIIB-Free Report) and Alexion (Nasdaq:ALXN-Free Report)....

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-04-03 12:29:29

Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to...

2014-03-27 12:30:26

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fzv3mt/global ) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on...

2014-03-26 08:23:02

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pt8tl4/treating ) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer through innovative drug development strategies have...

2014-03-26 08:22:56

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lnx8jm/treating ) has announced the addition of the "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) "Concise Analysis on Treating Refractory Hematological Malignancies for Multiple Myeloma", provides an overview of the therapies for Multiple Myeloma (Newly...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related